Nelson-Veniard Marie, Thambo Jean-Benoit
Hôpital cardiologique du Haut Lévêque, service des cardiopathies congénitales de l'enfant et de l'adulte, Bordeaux-Pessac, France.
Hôpital cardiologique du Haut Lévêque, service des cardiopathies congénitales de l'enfant et de l'adulte, Bordeaux-Pessac, France.
Bull Cancer. 2015 Jul-Aug;102(7-8):622-6. doi: 10.1016/j.bulcan.2015.03.014. Epub 2015 Apr 29.
Chemotherapy-induced cardiotoxicity is a major cause of morbidity and mortality in cancer survivor. The most clinically evident and best known cardiotoxicity is the anthracycline adverse effect with heart failure. Many cardiovascular adverse effects appear after cancer therapy: heart congestive failure, myocardial ischemia, hypertension, thromboembolic complications, arrhythmias and conduction disturbances. There are potential strategies to mitigate the risks of cardiac complications for cancer patients with physical examination, echocardiography and electrocardiogram. The management of the cardiotoxicity is variable.
化疗引起的心脏毒性是癌症幸存者发病和死亡的主要原因。临床上最明显且最为人所知的心脏毒性是蒽环类药物导致的心力衰竭不良反应。许多心血管不良反应在癌症治疗后出现：心脏充血性心力衰竭、心肌缺血、高血压、血栓栓塞并发症、心律失常和传导障碍。对于癌症患者，通过体格检查、超声心动图和心电图有一些潜在策略来降低心脏并发症的风险。心脏毒性的管理方法各不相同。
